ERBB2 and breast carcinoma: In whole population or HR+ or HR− subtype, HER2-positive patients had more tumors with Cluster 1 phenotype than HER2-low and HER2-zero patients and no difference in molecular clusters was observed between HER2-low and HER2-zero breast cancer patients (Fig. 4D).